Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Cellix Bio
AddedFeb 15, 2024
UpdatedJun 18, 2026
Cellix Bio

Cellix Bio

Series A

Cellix Bio: Advancing medical research for enhanced drug development and faster recovery in immune diseases.

HQ
Newark, NJ, US
Founded
2013
Overview
Compare
Fundraising
Employees

Cellix Bio's mission is to advance medical research by developing drug products for immune and related diseases. They focus on creating targeted therapies and proprietary molecular therapeutics that improve the efficacy, therapeutic index, bioavailability, and safety of approved drugs, aiming to treat chronic ailments more effectively and reduce recovery times.

Cellix Bio has made significant strides in enhancing drug attributes, benefiting healthcare professionals and patients alike. Their innovative approach to drug development has positioned them as a key player in the medical research field, contributing to faster and more effective treatments for chronic diseases.

Cellix Bio - Similar Companies

Cellino logo

Cellino

cellinobio.com

ImmuneXcite logo

ImmuneXcite

Xcell Biosciences logo

Xcell Biosciences

xcellbio.com

ZielBio logo

ZielBio

zielbio.com

Cellomics Technology logo

Cellomics Technology

cellomicstech.com

Celltheon logo

Celltheon

celltheon.com

Cell Care Therapeutics logo

Cell Care Therapeutics

cell-care.com

Diagnostic Biochips logo

Diagnostic Biochips

CiVi Biopharma logo

CiVi Biopharma

civibio.com

Cellics Therapeutics logo

Cellics Therapeutics

cellics.com

Sentien Biotechnologies logo

Sentien Biotechnologies

Khloris Biosciences logo

Khloris Biosciences

Innovation Pharmaceuticals logo

Innovation Pharmaceuticals

ipharminc.com

Cello Therapeutics logo

Cello Therapeutics

cellothera.com

Celvive logo

Celvive

Cellix Bio - Quick Facts

Who are Cellix Bio's competitors?

Companies similar to Cellix Bio include Cellino, ImmuneXcite, Xcell Biosciences and ZielBio.

When was Cellix Bio founded?

Cellix Bio was founded in 2013.

Where is Cellix Bio's headquarters located?

Cellix Bio's headquarters is located in Newark, NJ, US.

When was Cellix Bio's last funding round?

Cellix Bio's most recent funding round was for $500k (USD) in April 2019.

How much has Cellix Bio raised to-date?

As of Apr 2, 2019, Cellix Bio has raised a total of $14.3M (USD).

How many employees does Cellix Bio have?

Cellix Bio has 30 employees as of Feb 4, 2024.

Cellix Bio - Classification

Industry
  • Professional Service Companies
Ownership
  • Private
Technology
  • Biotech
Geographic Exposure
  • Global
Customer
  • Enterprise
Main Product
  • Medical Research
Tags
  • Consulting
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 13 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 623000Nursing and Residential Care Facilities
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 8000Health Services
  • 2830Drugs
  • 8040Offices And Clinics Of Other Health Practitioners
  • 2834Pharmaceutical Preparations
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified